Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Association among serum per- and polyfluoroalkyl substances, lipid profile and metabolic syndrome in Czech adults, HBM-EHES survey 2019

V. Puklová, N. Čapková, A. Fialová, A. Vavrouš, K. Žejglicová, M. Černá

. 2023 ; 31 (4) : 227-234. [pub] -

Language English Country Czech Republic

Document type Journal Article

Digital library NLK
Source

E-resources Online Full text

NLK Free Medical Journals from 2004
ProQuest Central from 2009-03-01 to 6 months ago
Medline Complete (EBSCOhost) from 2006-03-01 to 6 months ago
Nursing & Allied Health Database (ProQuest) from 2009-03-01 to 6 months ago
Health & Medicine (ProQuest) from 2009-03-01 to 6 months ago
Public Health Database (ProQuest) from 2009-03-01 to 6 months ago
ROAD: Directory of Open Access Scholarly Resources from 1993

OBJECTIVES: Per- and polyfluoroalkyl substances (PFASs) are a large group of persistent synthetic chemicals widely used commercially. They accumulate increasingly in all environmental components and enter the organisms, including humans. Some of them are associated with the risk of harm to health, among others with metabolic disorders. To test the associations between blood serum levels of PFASs and blood lipid profile as well as metabolic syndrome, we linked human biomonitoring with the Czech Health Examination Survey (CZ-EHES) conducted in 2019. METHODS: A total of 168 participants of the CZ-EHES survey aged 25-64 years were examined including anthropometrical data and analyses for serum PFAS and blood lipid levels. Extended model approach in multiple linear regression models was used for identification of the associations between serum levels of 11 PFASs and lipid profile components. The relation between PFAS serum levels and metabolic syndrome prevalence was tested using a logistic regression model. RESULTS: Six PFASs were detected over the limit of quantification in at least 40% cases and were examined in subsequent analyses: perfluorodecanoic acid (PFDA), perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), perfluoroundecanoic acid (PFUdA). The most dominant was PFOS with the mean value amounting to 4.81 ng/ml. After adjusting for potential confounders, we found a significant positive association between serum PFHxS and blood total cholesterol (p = 0.005) as well as LDL-cholesterol (p = 0.008). Significant positive association was also found between PFDA and HDL-cholesterol levels (p = 0.010). No significant associations were detected between PFASs and triglycerides, and between PFASs and metabolic syndrome. CONCLUSIONS: We found some evidence of a significant association between blood serum PFAS levels and blood cholesterol levels. Our results did not confirm an association between serum PFASs and the metabolic syndrome prevalence.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24002925
003      
CZ-PrNML
005      
20250312094528.0
007      
ta
008      
240215s2023 xr f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a7799 $2 doi
035    __
$a (PubMed)38309699
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Puklová, Vladimíra $u National Institute of Public Health, Prague, Czech Republic $7 mzk2007408334
245    10
$a Association among serum per- and polyfluoroalkyl substances, lipid profile and metabolic syndrome in Czech adults, HBM-EHES survey 2019 / $c V. Puklová, N. Čapková, A. Fialová, A. Vavrouš, K. Žejglicová, M. Černá
520    9_
$a OBJECTIVES: Per- and polyfluoroalkyl substances (PFASs) are a large group of persistent synthetic chemicals widely used commercially. They accumulate increasingly in all environmental components and enter the organisms, including humans. Some of them are associated with the risk of harm to health, among others with metabolic disorders. To test the associations between blood serum levels of PFASs and blood lipid profile as well as metabolic syndrome, we linked human biomonitoring with the Czech Health Examination Survey (CZ-EHES) conducted in 2019. METHODS: A total of 168 participants of the CZ-EHES survey aged 25-64 years were examined including anthropometrical data and analyses for serum PFAS and blood lipid levels. Extended model approach in multiple linear regression models was used for identification of the associations between serum levels of 11 PFASs and lipid profile components. The relation between PFAS serum levels and metabolic syndrome prevalence was tested using a logistic regression model. RESULTS: Six PFASs were detected over the limit of quantification in at least 40% cases and were examined in subsequent analyses: perfluorodecanoic acid (PFDA), perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), perfluoroundecanoic acid (PFUdA). The most dominant was PFOS with the mean value amounting to 4.81 ng/ml. After adjusting for potential confounders, we found a significant positive association between serum PFHxS and blood total cholesterol (p = 0.005) as well as LDL-cholesterol (p = 0.008). Significant positive association was also found between PFDA and HDL-cholesterol levels (p = 0.010). No significant associations were detected between PFASs and triglycerides, and between PFASs and metabolic syndrome. CONCLUSIONS: We found some evidence of a significant association between blood serum PFAS levels and blood cholesterol levels. Our results did not confirm an association between serum PFASs and the metabolic syndrome prevalence.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a látky znečišťující životní prostředí $7 D004785
650    12
$a metabolický syndrom $x epidemiologie $7 D024821
650    _2
$a sérum $7 D044967
650    _2
$a lipidy $7 D008055
650    12
$a fluorokarbony $7 D005466
650    _2
$a cholesterol $7 D002784
650    12
$a kyseliny dekanové $7 D003652
650    12
$a kyseliny sulfonové $7 D013451
650    12
$a kyseliny alkansulfonové $7 D017738
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čapková, Naďa $u National Institute of Public Health, Prague, Czech Republic $7 xx0093653
700    1_
$a Fialová, Alena $u National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Czech Republic $7 stk2008461869
700    1_
$a Vavrouš, Adam $u National Institute of Public Health, Prague, Czech Republic $7 _AN087637
700    1_
$a Žejglicová, Kristýna $u National Institute of Public Health, Prague, Czech Republic $7 xx0088521
700    1_
$a Černá, Milena, $d 1943- $u National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University in Prague, Czech Republic $7 nlk19990074185
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 31, č. 4 (2023), s. 227-234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38309699 $y Pubmed
910    __
$a ABA008 $b B 1829 $c 562 $y p $z 0
990    __
$a 20240215 $b ABA008
991    __
$a 20250312094535 $b ABA008
999    __
$a ok $b bmc $g 2283461 $s 1212661
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 31 $c 4 $d 227-234 $e - $i 1210-7778 $m Central European journal of public health $n Cent Eur J Public Health $x MED00001083
LZP    __
$b NLK124 $a Pubmed-20240215

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...